News

Sunovion’s Below-the-Tongue Therapy Eases Parkinson’s Movement Difficulties, Trial Shows

Sunovion Pharmaceuticals’ below-the-tongue version of a Parkinson’s therapy was able to ease patients’ movement difficulties after the standard therapy levodopa wore off, a Phase 3 clinical trial showed. Patients also tolerated the treatment — known as apomorphine sublingual film — well, the preliminary results showed. Sublingual means below the tongue, so the therapy’s full…

NIH Creates Huge Public-Private Partnership to Try to Speed Parkinson’s Therapy Development

The U.S. National Institutes of Health is starting a pioneering, multi-pronged public-private partnership program to try to accelerate the development of Parkinson’s treatments. What makes it special is how big it is. The NIH-led collaboration includes government, pharmaceutical companies, life science companies and non-profit organizations. The partners are calling the collaboration AMP…